Revascularization of diabetic patients: Are drug-eluting stents the solution?

Italian Heart Journal

Volumn 6, Issue 6, 2005, Pages 507-513

  Guagliumi, Giulio ^a   Musumeci, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Coronary angioplasty; Diabetes mellitus; Stents

Indexed keywords

BIOMATERIAL;

BLOOD VESSEL TRANSPLANTATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EQUIPMENT; HEART MUSCLE REVASCULARIZATION; HUMAN; INSTRUMENTATION; METHODOLOGY; REVIEW; STENT;

BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY DISEASE; DIABETES MELLITUS; EQUIPMENT SAFETY; HUMANS; MYOCARDIAL REVASCULARIZATION; STENTS;

EID: 26944447931     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-85.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
3. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes 1989; 38: 504-9.
4. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
5. Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109: 476-80.
6. Sabate M, Angiolillo DJ, Alfonso F, et al. Sirolimus-eluting stent to prevent restenosis after stenting in diabetic patients with de novo coronary stenoses. The DIABETES (Diabetes and Sirolimus-Eluting Stent) Trial: 9-month angiographic results. (abstr) Am J Cardiol 2004; 94 (Suppl 6A): 75E.
7. Guagliumi G, Urban P, Wijns W, et al. Real-life impact of sirolimus-eluting stent implantation in treating diabetic patients: a 6-month follow-up report from the international e-CYPHER registry. (abstr) Circulation 2004; 110: III-647.
8. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987; 60: 20B-28B.
9. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103: 1967-71.
10. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation 1998; 98: 2126-32.
11. Iakovou I, Sangiorgi G, Colombo A, et al. Incidence and predictors of stent thrombosis after paclitaxel and sirolimus-eluting stent implantation in the "real world". (abstr) Circulation 2004; 110: III-688.
12. Urban P, Gerslick A, Guagliumi G. Predictors of major adverse cardiac events at 6 months after implantation of sirolimus-eluting stents: a report from the e-CYPHER Registry. (abstr) Circulation 2004; 110: III-527.
13. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart 2003; 89: 133-8.
14. Guagliumi G. Serial in-vivo evaluation of endovascular response to stent implants: an angioscopic pathologic comparison in normal porcine arteries. (abstr) Jpn Circ J 1999; 63: I-116.
15. Jokl R, Colwell JA. Arterial thrombosis and atherosclerosis in diabetes. Diabetes Metab Rev 1997; 5: 1-15.
16. Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 1981; 97: 87-96.
17. Martina V, Bruno GA, Trucco F, et al. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost 1998; 79: 520-2.
18. Sarji KE, Kleinfelder J, Brewington P, Gonzalez J, Hempling H, Colwell JA. Decreased platelet vitamin C in diabetes mellitus: possible role in hyperaggregation. Thromb Res 1979; 15: 639-50.
19. Tschoepe D, Rauch U, Schwippert B. Platelet-leukocytecross-talk in diabetes mellitus. Horm Metab Res 1997; 29: 631-5.
20. Leet H, Paton RC, Passa P, Caen JP. Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects. Thromb Res 1981; 24: 143-50.
21. Kabbani SS, Watkins MW, Ashikaga T, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 181-6.
22. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. Platelet dysfunction following a 300 mg clopidogrel loading dose in type 2 diabetes undergoing coronary stenting. (abstr) J Am Coll Cardiol 2004: 43: 65A.
23. Feit F, Brooks MM, Sopko G, et al. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. Circulation 2000; 101: 2795-802.
24. Legrand VM, Serruys PW, Unger F, et al, for the Arterial Revascularization Therapy Study (ARTS) Investigators. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004; 109: 1114-20.
25. Serruys PW, Hamm C, Macaya C, et al. Arterial Revascularization Therapies Study: Part II of the Sirolimus-Eluting Bx Velocity Balloon Expandable Stent in the Treatment of Patients with Multivessel De Novo Coronary Artery Lesions. (abstr) Am J Cardiol 2004; 94 (Suppl 6A): 69E.